Searched for
PHARMACEUTICALS
US tariff proposal wake-up call for Indian pharma to diversify, innovate: ExpertsUS pharma tariffs: Experts have urged a shift towards global diversification and prioritising innovation for Indian pharma to lessen market...- Parliament watch: FTA exports rise, PLI payouts growIndia's merchandise exports to its free trade agreement (FTA) partner countries rose 25% year-on-year to $43.14 billion in the April-June q...
- Pharma deal activity hits four-quarter low, but mega Sun Pharma acquisition drives valueIndia's pharma and healthcare sector recorded 65 deals worth $13.9 billion in Q2 CY2026, with volumes falling 17% quarter-on-quarter to a f...
- Organon shareholders approve Sun Pharma's $11.75-bn acquisition proposalSun Pharmaceutical Industries Ltd announced shareholder approval for its Organon & Co acquisition. This significant milestone moves the pro...
- Akums to acquire Oriflame India's manufacturing businessAkums Drugs and Pharmaceuticals will acquire Oriflame India's manufacturing business. This significant deal is valued at fifty-six crore ru...
- Pharma stocks slide as Trump's 100% generic drug tariff plan spooks investorsIndian drug shares declined Wednesday following US President Trump's tariff announcement. These proposed tariffs will significantly impact ...
- Tariffs alone will not produce sustainable generic medicine in US: IPAThe Indian Pharmaceutical Alliance believes tariffs alone will not build US generic drug manufacturing. Broader reforms are needed for fair...
- Food products lead PLI job creation, outpace electronics and pharmaFood processing leads PLI employment, creating jobs with minimal investment. Electronics manufacturing attracted significant capital but ge...
- Explained: What Donald Trump's up to 200% pharma tariffs mean for Indian investorsDonald Trump's announcement of tariffs of up to 200% on pharmaceutical imports triggered a selloff in Indian pharma stocks. However, analys...
- Indian pharma firms may yet survive Trump's 200% tariff bombshellDonald Trump's proposed up to 200% tariff on generic drug imports has raised concerns for Indian pharma companies, but industry experts say...
- 200% Trump tariff shock? India’s cheap pills may still beat US rivalsUS President Donald Trump's proposed tariffs of up to 200% on imported generic medicines could put pressure on India's pharmaceutical expor...
- Trump’s 100% generic drug duty threatens US low-cost supplyPresident Donald Trump has given generic drugmakers two years to shift manufacturing to the US or face 100% import tariffs from August 2028...
- Trump's Generic Drug Tariffs Explained: What it means for Indian pharma before the 200% stormTrump's generic drug tariffs plan provides Indian drugmakers a two-year duty-free window. This allows companies time to reassess manufactur...
- Trump's 200% drug tariff plan: Is India's pharma industry about to face an economic storm?The United States is set to implement a phased approach to tariffs on generic drug imports, beginning at zero percent and escalating to one...
- Hikal commissions cGMP pilot plant in Pune to strengthen pharmaceutical developmentHikal has commissioned an enhanced cGMP pilot plant at its Pune campus to strengthen its integrated capabilities for pharmaceutical develop...
- Sun Pharma, Cipla & other pharma stocks shed over 2% as Trump announces up to 200% tariffs on generic drugs from 2028Pharma stocks, including Sun Pharma, Cipla, Lupin and Dr Reddy's, fell up to 2.5% after US President Donald Trump announced a phased tariff...
- ICMR licenses cancer, vaccine technologies to Emcure, Biological EThe Indian Council of Medical Research has licensed three new biomedical technologies. These innovations aim to advance cancer treatment an...
- Glenmark gets USFDA nod for expanded use of RYALTRIS nasal sprayGlenmark Pharmaceuticals announced US FDA approval for RYALTRIS nasal spray. This approval expands its use to children aged six to twelve y...
- Natco Pharma shares surge 5% after US FDA's tentative nod Olaparib tabletsNatco Pharma shares rose sharply on Monday after the U.S. FDA granted tentative approval for its generic Olaparib tablets, a bioequivalent ...
- Alembic Pharma partner NATCO gets USFDA tentative nod for generic Olaparib tablets; US market size at USD 1.4 bnAlembic Pharmaceuticals and NATCO Pharma received tentative USFDA approval for generic Olaparib tablets. This approval is for a cancer drug...
Load More
